Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Methods Mol Biol. 2023;2706:191-200. doi: 10.1007/978-1-0716-3397-7_14.
Covalent inhibitors are emerging as a promising therapeutic means for efficient and sustained targeting of key disease-driving proteins. As for classic non-covalent inhibitors, understanding target engagement and selectivity is essential for determining optimal dosing and limiting potential on- or off-target toxicity. Here, we present a complementary activity-based protein profiling (ABPP) strategy for unbiased proteome-wide profiling of cysteine-reactive inhibitors based on two orthogonal approaches. We illustrate the use of clickable alkyne probes for in-gel fluorescence and mass spectrometry studies using a series of therapeutic XPO1 inhibitors as an example.
共价抑制剂作为一种有前途的治疗手段,正在出现,可有效且持续地针对关键疾病驱动蛋白进行靶向治疗。与经典的非共价抑制剂一样,了解靶标结合和选择性对于确定最佳剂量和限制潜在的靶标或非靶标毒性至关重要。在这里,我们提出了一种基于两种正交方法的无偏全蛋白质组范围内半胱氨酸反应性抑制剂的活性蛋白质组学(ABPP)分析策略。我们以一系列治疗性 XPO1 抑制剂为例,展示了使用可点击炔烃探针进行胶内荧光和质谱研究的方法。